Enzymatica publ AB (ENZY) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.085x

Based on the latest financial reports, Enzymatica publ AB (ENZY) has a cash flow conversion efficiency ratio of -0.085x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-11.57 Million ≈ $-1.24 Million USD) by net assets (Skr135.68 Million ≈ $14.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Enzymatica publ AB - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Enzymatica publ AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Enzymatica publ AB debt and liabilities for a breakdown of total debt and financial obligations.

Enzymatica publ AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Enzymatica publ AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Sunsuria Bhd
KLSE:3743
-0.024x
TROPHY GAMES Development AS
CO:TGAMES
0.145x
Territorial Bancorp Inc
NASDAQ:TBNK
-0.003x
Teuton Resources Corp.
V:TUO
-0.012x
International Development & Investment Corp
VN:IDI
-0.101x
Formet Celik Kapi Sanayi ve Ticaret AS
IS:FORMT
0.033x
Pancontinental Energy NL
AU:PCL
-0.047x
International Media Acquisition Corp
NASDAQ:IMAQ
0.023x

Annual Cash Flow Conversion Efficiency for Enzymatica publ AB (2009–2024)

The table below shows the annual cash flow conversion efficiency of Enzymatica publ AB from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Enzymatica publ AB worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr176.37 Million
≈ $18.98 Million
Skr-60.51 Million
≈ $-6.51 Million
-0.343x +34.76%
2023-12-31 Skr76.61 Million
≈ $8.24 Million
Skr-40.29 Million
≈ $-4.34 Million
-0.526x -2.86%
2022-12-31 Skr126.29 Million
≈ $13.59 Million
Skr-64.57 Million
≈ $-6.95 Million
-0.511x -78.12%
2021-12-31 Skr124.97 Million
≈ $13.45 Million
Skr-35.87 Million
≈ $-3.86 Million
-0.287x -187.36%
2020-12-31 Skr106.65 Million
≈ $11.48 Million
Skr-10.65 Million
≈ $-1.15 Million
-0.100x +68.32%
2019-12-31 Skr119.20 Million
≈ $12.83 Million
Skr-37.58 Million
≈ $-4.04 Million
-0.315x -74.80%
2018-12-31 Skr159.66 Million
≈ $17.18 Million
Skr-28.79 Million
≈ $-3.10 Million
-0.180x +11.46%
2017-12-31 Skr110.70 Million
≈ $11.91 Million
Skr-22.55 Million
≈ $-2.43 Million
-0.204x +24.73%
2016-12-31 Skr142.04 Million
≈ $15.29 Million
Skr-38.43 Million
≈ $-4.14 Million
-0.271x +84.20%
2015-12-31 Skr21.98 Million
≈ $2.37 Million
Skr-37.65 Million
≈ $-4.05 Million
-1.712x -162.87%
2014-12-31 Skr62.42 Million
≈ $6.72 Million
Skr-40.67 Million
≈ $-4.38 Million
-0.651x +44.40%
2013-12-31 Skr15.73 Million
≈ $1.69 Million
Skr-18.43 Million
≈ $-1.98 Million
-1.172x -127.13%
2012-12-31 Skr14.06 Million
≈ $1.51 Million
Skr-7.25 Million
≈ $-780.54K
-0.516x +64.79%
2011-12-31 Skr3.31 Million
≈ $356.64K
Skr-4.86 Million
≈ $-522.58K
-1.465x -1395.19%
2009-12-31 Skr-901.48K
≈ $-97.01K
Skr-101.99K
≈ $-10.98K
0.113x --

About Enzymatica publ AB

ST:ENZY Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$66.35 Million
Skr616.55 Million SEK
Market Cap Rank
#20791 Global
#372 in Sweden
Share Price
Skr2.54
Change (1 day)
+2.01%
52-Week Range
Skr1.65 - Skr3.48
All Time High
Skr770.83
About

Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.